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tumor growth in vitro and in vivo and prolong overall survival.
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Background: PTEN is an important phosphatase, suppressing
the phosphatidylinositol-3-kinase/Akt pathway which induces
apoptosis. p27kip1 binds to cyclin-E/Cdk2 and prevents mitosis.
The inactivation of the tumor suppressor genes has been associ-
ated with many different types of cancer including the prostatic
carcinoma (PCa). In this study we investigated the influence of
an antihormonal treatment on the expression of PTEN and
p27kip1 in PCa.
Methods: 82 prostate cancer patients treated with antiandro-
gens or LH-RH analogs or a combination therapy between 1 and
77 weeks (mean 9.7 ± 1.2) were included in this study. The expres-
sion of PTEN and p27kip1 were analyzed by immunhistochemistry
and an immunreactive score. The results were compared with 183
untreated cases of a previous study.
Results: PTEN expression levels correlated with the duration of
antihormonal therapy: significantly more PTEN positive cases
were found after 3 weeks antihormonal therapy (p = 0.0003).
PTEN-expression compared to untreated tumors showed a signif-
icantly stronger PTEN-expression in treated tumors (p = 0.03). A
nuclear expression of p27kip1 was more frequent in tumors after
4 weeks of treatment compared to tumors treated less than 4
weeks (p = 0.015).
Conclusions: Both PTEN and p27kip1 expression was increased
after 4 weeks of antihormonal treatment. This fact might indicate
an early stress reaction of the tumor cells due to the androgen-
deprivation therapy.
doi:10.1016/j.ejcsup.2006.04.101
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Background: GSK3beta is involved in the control of gene expres-
sion via the regulation of transcription factors, including estrogen
receptor alpha (ERalpha). Recently, we discovered involvement of
GSK3beta in estrogen-independent and estrogen-dependent acti-
vation of ERalpha, respectively.1,2 While phosphorylation of ERal-
pha appears to be crucial for its activation, the impact ofGSK3beta on the estrogen-dependent regulation of ERalpha func-
tion and activity remains to be clarified.
Methods: Phosphorylation of ERalpha by GSK3beta was analysed
by in vitro kinase assays. Thereafter, the effects of GSK3 inhibitors
on ERalpha phosphorylation and activation were analysed in
breast cancer cells using Western blot and luciferase reporter
assays. Further experiments using siRNA technology and trans-
fection of cells with GSK3beta mutants were performed to inves-
tigate the effects of GSK3beta regarding ERalpha signalling
pathway.
Results: In vitro kinase assays first depicted that GSK3beta phos-
phorylated ERalpha at Ser-118. Moreover, the addition of a GSK3
inhibitor (LiCl) on MCF-7 cells in culture stimulated with estradiol
(E2) led to a decrease in Ser-118 phosphorylation and to an inhibi-
tion of ERalpha-controlled luciferase activity. In agreement with
the previous observations, the knock-down of GSK3 by use of
siRNA resulted in decreased basal and E2-induced ERalpha phos-
phorylation at Ser-118 as well as in reduced luciferase activity.
Conclusion: We suggest that GSK3beta plays an important role
in the estrogen-dependent regulation of ERalpha function and
activity.
doi:10.1016/j.ejcsup.2006.04.102
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Background: ErbB-receptors/ligands are involved in several can-
cers. Plasma cells expressing the heparin-sulphate proteoglycan
(HSPG) syndecan-1 (CD138) attach heparin-binding growth fac-
tors.1 The aim of this study is to identify new targets in the ther-
apy of multiple myeloma (MM).
Methods: Samples of 65 patients (CD138-purified MM-cells (MMC)
and bone-marrow-microenvironment (BMME)), 7 normal bone-
marrow-plasma-cell-samples (BMPC) and 20 human-myeloma-
cell-lines were studied. The expression of the 4 ErbB-receptors/
ligands on MMC and BMME will be assessed by real-time RT-PCR
and Affymetrix U133 A+B DNA-microarrays. BMME-cells from
MM-patients were exposed to PD169540 (a pan-ErbB-inhibitor)
and IRESSA (ErbB1-specific).
Results: ErbB1 and ErbB2 are expressed by BMPC, MMC and the
BMME. ErbB3 and ErbB4 are expressed by a subgroup of MMC. 7/
10 ErbB-ligands are expressed by MMC and/or the BBME. Myeloma
cell growth is stimulated by the 3 ErbB-ligands that are able to
attach HSPG (i.e amphiregulin, HB-EGF and neuregulin-1) via
binding to syndecan-1. PD169540 and IRESSA induced apoptosis
of primary MMC from 10/14 and 4/14 patients in vitro,
respectively.1,2
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approach in MM. A clinical trial testing the ErbB1-inhibitor cetux-
imab and correlating response with the expression of ErbB-recep-
tors/ligands is in preparation at the University Hospitals of
Cologne, Heidelberg and Montpellier.
doi:10.1016/j.ejcsup.2006.04.103
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Background: Malignant melanoma, notorious for its poor
response to currently available therapeutics, is one of the fastest
increasing cancers. Therefore, development of new alternative
treatment strategies (including immunotherapeutic ones) is
extremely important. This approach requires an establishment
of the reliable animal melanoma model that resembles human
melanoma with respect to etiology, tumor genetics, histopathol-
ogy and clinical development. We use a recently developed mouse
model of spontaneous skin melanoma, in which ret transgene (tg)
is expressed in melanocytes under the control of metallothio-
nein-I promoter (MT/Ret). Activity of the receptor tyrosine kinase,
Ret, is upregulated during the disease progression.
Methods: Immunohistology, flow cytometry, ELISPOT, ELISA, tet-
ramer staining and in vivo kill.
Results: After a short latency (2–4 months), around 30% of mice
develop skin melanoma metastasizing to lymph nodes, lungs and
brain. We found that tumors expressed melanoma associated
antigens tyrosinase, tyrosinase related protein (TRP)-1, TRP-2
and gp100, which could be applied as targets for the immunother-
apy. Ret-tg mice without tumors could mount both antigen-
unspecific (stimulation with Con A or with CD3/CD28 antibodies)
and antigen-specific (ovalbumin or TRP-2 derived peptide) T-cell
reactions, which were downregulated in melanoma bearing Ret-
tg mice. In addition, Ret-tg mice have more effector memory
and regulatory T cells than healthy (wild type) mice.
Conclusion: New strategies of melanoma immunotherapy in
this spontaneous melanoma mouse model (including therapy
with memory T cells together with dendritic cells or depletion
of regulatory T cells) will be discussed.
doi:10.1016/j.ejcsup.2006.04.104
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Background: Protein kinase (PK) inhibitors are candidates for
modifying the response of tumour cells to anticancer agents suchas radiotherapy. The purpose of the present study was to compare
inhibition of the PI3K/Akt survival pathway by specific concentra-
tions of different PK inhibitors with changes in the radiosensitiv-
ity of glioblastoma cell lines in vitro.
Methods: Glioblastoma cell lines U343MG, U87MG and U251MG
were used. PI3K inhibitors (Wortmannin; LY294002) and receptor
tyrosine kinase (RTK) inhibitors (AG1296; AG1478; erlotinib) were
added to cultures before or after irradiation. The phosphorylation
state of Akt was detected by Western blotting. The cellular radio-
sensitivity was measured by the colony formation assay fitting
survival curves with the linear-quadratic model.
Results: The inhibitory effect of Wortmannin and LY294002 on
Akt phosphorylation depended on the cell line. However, whereas
downregulation to a variable degree was observed with 50 nM
Wortmannin, radiosensitization required micromolar concentra-
tions. RTK inhibitors had little influence on Akt phosphorylation
but moderately sensitised cells to radiation. However, the sensi-
tising effect was similar whether the inhibitor was added before
or after irradiation.
Conclusions: The results did not support a correlation between
radiosensitisation and inhibition of the PI3K/Akt survival path-
way. RTK inhibitors were not required to be present during irradi-
ation in order to sensitise cells and thus cannot be considered
classical radiosensitisers. Instead they may exert their inhibitory
effect on clonogenicity. We further conclude that signal transduc-
tion differs between glioblastoma cell lines and propose that this
might have prognostic value in vivo.
doi:10.1016/j.ejcsup.2006.04.105
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Introduction: The centrosome is a small organelle which con-
sists of two centrioles and the pericentriolar matrix. It functions
as the microtubule-organizing center of eukaryotic cells and plays
a central role in chromosome segregation and cytokinesis. Many
human malignancies harbor centrosomal aberrations, which are
caused by deregulation of centrosome duplication or cytokinesis
failure. Cells with supernumerary centrosomes usually form mul-
tipolar spindles leading to aberrant mitoses with consecutive
chromosome missegregation. To regain secondary karyotype sta-
bility after clonal selection, some tumor cells coalesce their extra
centrosomes by a poorly defined mechanism into two spindles
poles in order to divide properly.
Method: Here, we describe an automated screening strategy
designed to identify small molecules – produced by hundreds of
